Abstract: The present invention relates to a transformer and, more specifically, to a transformer including a secondary coil portion on which a conductive plate is stacked. A transformer according to one embodiment of the present invention can comprise: a bobbin; a core portion coupled to the bobbin along the outer side of the bobbin; and a plurality of conductive plates inserted into the bobbin and stacked in a thickness direction.

Abstract: The present invention relates to a transformer and, more specifically, to a transformer including a secondary coil portion on which a conductive plate is stacked. A transformer according to one embodiment of the present invention can comprise: a bobbin; a core portion coupled to the bobbin along the outer side of the bobbin; and a plurality of conductive plates inserted into the bobbin and stacked in a thickness direction.

Abstract: A method for increasing dendritic cell migration ability, and a use thereof are disclosed. A method according to one aspect can increase the migration ability of mature dendritic cells and increase the induction, by dendritic cells, of inflammatory cytokine production, T lymphocyte proliferation and T lymphocyte polarization, and thus can be used for the prevention or treatment of immune-related diseases.

Abstract: Provided are the tolerogenic dendritic cells for treating a myocardial infarction and a method for preparing the same, and more particularly, the tolerogenic dendritic cells for treating a myocardial infarction, which can treat cardiac insufficiency that occurs by excessive remodeling of left ventricle in the heart muscle recovery process after an acute myocardial infarction, and a method for preparing the tolergenic dendritic cells. According to the present invention, the inflammatory reaction and the excessive remodeling of left ventricle in the heart muscle recovery process after a myocardial infarction can be inhibited, and thus, the incidence rate of cardiac insufficiency can be significantly reduced, thereby being effectively used for treating a myocardial infarction.

Abstract: Provided are the tolerogenic dendritic cells for treating a myocardial infarction and a method for preparing the same, and more particularly, the tolerogenic dendritic cells for treating a myocardial infarction, which can treat cardiac insufficiency that occurs by excessive remodeling of left ventricle in the heart muscle recovery process after an acute myocardial infarction, and a method for preparing the tolergenic dendritic cells. According to the present invention, the inflammatory reaction and the excessive remodeling of left ventricle in the heart muscle recovery process after a myocardial infarction can be inhibited, and thus, the incidence rate of cardiac insufficiency can be significantly reduced, thereby being effectively used for treating a myocardial infarction.

Abstract: Disclosed are a composition including gelsolin as an effective ingredient for inducing differentiation into a dendritic cell, a method of inducing differentiation by using the composition, and a vaccine composition for treating cancer or an immune-mediated disease. In addition, a composition including gelsolin as an effective ingredient for inducing differentiation into a dendritic cell and a method of inducing differentiation into a dendritic cell by treating an immature dendritic cell with gelsolin are also disclosed. Further, a dendritic cell differentiated by using the method of inducing differentiation into the dendritic cell and a vaccine composition including the dendritic cell as an effective ingredient for treating cancer or an immune-mediated disease are disclosed.

Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.

Abstract: The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis through the activity of the suppression of auto-immune responses.

Abstract: A method for preparing dendritic cells which have an enhanced potential to suppress immune responses, method for suppressing immune response by comprising administering them, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating or preventing various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells ensures the cells to be effectively used as an immunosuppressive agent.

Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis, particularly chronic synovitis.

Abstract: A lens includes a convex surface formed in an outer surface thereof facing away from a light source to uniformly distribute light emitted from the light source; a concave surface concaved inward from an inner region of the convex surface, around an optical axis; and a convex portion convexed outward from a central region of the concave surface, which the optical axis intersects, in order to enhance quantity of light around the optical axis. The lens refracts light beams falling onto the respective areas thereof at different angles, thereby producing a uniform light distribution within a specific lighting range, but does not create a dark area around an optical axis.